» Articles » PMID: 32225033

Sex-Related Differences of the Effect of Lipoproteins and Apolipoproteins on 10-Year Cardiovascular Disease Risk; Insights from the ATTICA Study (2002-2012)

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2020 Apr 1
PMID 32225033
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

The sex-specific effect of lipid-related biomarkers on 10-year first fatal/non fatal cardiovascular disease (CVD) incidence was evaluated. ATTICA study was conducted during 2001-2012. = 1514 men and = 1528 women (>18 years) from greater Athens area, Greece were recruited. Follow-up (2011-2012) was achieved in = 2020 participants. Baseline lipid profile was measured. Overall CVD event was 15.5% ( = 317) (19.7% in men and 11.7% in women, ). High density lipoprotein cholesterol (HDL-C) and triglycerides (TAG) were independently associated with CVD in women; per 10 mg/dL HDL-C increase, hazard ratio (HR) = 0.73, 95% confidence interval (95% CI) (0.53, 1.00); and per 10 mg/dL TAG increase, HR = 1.10, 95% CI (1.00, 1.21). Apolipoprotein A1 (ApoA1) (per 10 mg/dL increase, HR = 0.90, 95% CI (0.81, 0.99)) was inversely associated with CVD in women, while a positive association with apolipoprotein B100 (ApoB100) was observed only in men (per 10 mg/dL increase, HR = 1.10, 95% CI (1.00, 1.21)). Non-HDL-C was associated with CVD in the total sample (HR = 1.10, 95% CI (1.00, 1.21)) and in women (HR = 1.10, 95% CI (1.00, 1.21)); a steep increase in HR was observed for values >185 mg/dL in the total sample and in men, while in women, a raise in CVD risk was observed from lower values (>145 mg/dL). As for non-HDL-C/HDL-C and TC/HDL-C ratios, similar trends were observed. Beyond the common cholesterol-adjusted risk scores, reclassifying total CVD risk according to other lipid markers may contribute to early CVD prevention. Biomarkers such as HDL-C, non-HDL-C, and TAG should be more closely monitored in women.

Citing Articles

Association of cumulative non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio with the risk of cardiometabolic disease.

Liu L, Liu S, Liao Y, Zhang X, Wang M, Lin L Front Cardiovasc Med. 2024; 11:1500025.

PMID: 39635266 PMC: 11614763. DOI: 10.3389/fcvm.2024.1500025.


The Predictive Value of Atherogenic Index of Plasma, Non- High Density Lipoprotein Cholesterol (Non-HDL-C), Non-HDL-C/HDL-C, and Lipoprotein Combine Index for Stroke Incidence and Prognosis in Maintenance Hemodialysis Patients.

Ma L, Sun F, Zhu K, Han Q, Sun Q Clin Interv Aging. 2024; 19:1235-1245.

PMID: 38978964 PMC: 11230120. DOI: 10.2147/CIA.S461150.


The relationship between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and hyperuricaemia.

Wang Z, Wu M, Du R, Tang F, Xu M, Gu T Lipids Health Dis. 2024; 23(1):187.

PMID: 38907262 PMC: 11191326. DOI: 10.1186/s12944-024-02171-4.


Cumulative non-high-density lipoprotein cholesterol burden and risk of atherosclerotic cardiovascular disease: a prospective community-based study.

Guan X, Shi H, Xu S, Chen Y, Zhang R, Dong Y Front Cardiovasc Med. 2023; 10:1105342.

PMID: 37273877 PMC: 10232823. DOI: 10.3389/fcvm.2023.1105342.


Lipids in Atherosclerosis: Pathophysiology and the Role of Calculated Lipid Indices in Assessing Cardiovascular Risk in Patients with Hyperlipidemia.

Gaggini M, Gorini F, Vassalle C Int J Mol Sci. 2023; 24(1).

PMID: 36613514 PMC: 9820080. DOI: 10.3390/ijms24010075.


References
1.
Mora S, Buring J, Ridker P, Cui Y . Association of high-density lipoprotein cholesterol with incident cardiovascular events in women, by low-density lipoprotein cholesterol and apolipoprotein B100 levels: a cohort study. Ann Intern Med. 2011; 155(11):742-50. PMC: 3233986. DOI: 10.7326/0003-4819-155-11-201112060-00006. View

2.
Di Angelantonio E, Gao P, Pennells L, Kaptoge S, Caslake M, Thompson A . Lipid-related markers and cardiovascular disease prediction. JAMA. 2012; 307(23):2499-506. PMC: 4211641. DOI: 10.1001/jama.2012.6571. View

3.
Kouvari M, Yannakoulia M, Souliotis K, Panagiotakos D . Challenges in Sex- and Gender-Centered Prevention and Management of Cardiovascular Disease: Implications of Genetic, Metabolic, and Environmental Paths. Angiology. 2018; 69(10):843-853. DOI: 10.1177/0003319718756732. View

4.
Rader D, Hovingh G . HDL and cardiovascular disease. Lancet. 2014; 384(9943):618-625. DOI: 10.1016/S0140-6736(14)61217-4. View

5.
Manson J, Bassuk S . Biomarkers of cardiovascular disease risk in women. Metabolism. 2014; 64(3 Suppl 1):S33-9. PMC: 4310209. DOI: 10.1016/j.metabol.2014.10.028. View